Late Breaking Abstract - Efficacy of DPP1 inhibition with brensocatib in subgroups of patients with bronchiectasis- the WILLOW study

J. Chalmers (Dundee, United Kingdom), C. Haworth (Cambridge, United Kingdom), M. Metersky (Farmington, United States of America), M. Loebinger (London, United Kingdom), F. Blasi (Milan, Italy), O. Sibila (Barcelona, Spain), A. O'Donnell (Washington DC, United States of America), E. Sullivan (Bridgewater, NJ, United States of America), K. Mange (Bridgewater, NJ, United States of America), C. Fernandez (Bridgewater, NJ, United States of America), J. Zou (Bridgewater, NJ, United States of America), C. Daley (Dundee (Angus), United States of America)

Source: Virtual Congress 2020 – ALERT: Infection in adults and children

Session: ALERT: Infection in adults and children
Session type: Clinical trials session
Number: 4135

Disease area: Airway diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Chalmers (Dundee, United Kingdom), C. Haworth (Cambridge, United Kingdom), M. Metersky (Farmington, United States of America), M. Loebinger (London, United Kingdom), F. Blasi (Milan, Italy), O. Sibila (Barcelona, Spain), A. O'Donnell (Washington DC, United States of America), E. Sullivan (Bridgewater, NJ, United States of America), K. Mange (Bridgewater, NJ, United States of America), C. Fernandez (Bridgewater, NJ, United States of America), J. Zou (Bridgewater, NJ, United States of America), C. Daley (Dundee (Angus), United States of America). Late Breaking Abstract - Efficacy of DPP1 inhibition with brensocatib in subgroups of patients with bronchiectasis- the WILLOW study. 4135

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.